FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: This FDA approval is significant for Virginia as it provides a new treatment option for the estimated 2,000 individuals in the state living with sickle cell disease, many of whom are children, potentially improving their quality of life and reducing healthcare burdens.

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).